AYAL Capital Advisors Ltd Makes New $376,000 Investment in Profound Medical Corp. (NASDAQ:PROF)

AYAL Capital Advisors Ltd bought a new stake in Profound Medical Corp. (NASDAQ:PROF) during the 4th quarter, HoldingsChannel.com reports. The fund bought 50,000 shares of the company’s stock, valued at approximately $376,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in Profound Medical during the 4th quarter valued at about $114,000. MTM Investment Management LLC increased its holdings in Profound Medical by 10.4% in the 4th quarter. MTM Investment Management LLC now owns 18,575 shares of the company’s stock worth $139,000 after buying an additional 1,750 shares during the period. Marshall Wace LLP increased its holdings in Profound Medical by 201.6% in the 4th quarter. Marshall Wace LLP now owns 36,216 shares of the company’s stock worth $272,000 after buying an additional 24,208 shares during the period. Northwest & Ethical Investments L.P. raised its position in Profound Medical by 94.9% during the 4th quarter. Northwest & Ethical Investments L.P. now owns 46,200 shares of the company’s stock worth $346,000 after buying an additional 22,500 shares during the last quarter. Finally, Truist Financial Corp acquired a new stake in Profound Medical during the 4th quarter valued at approximately $376,000. Hedge funds and other institutional investors own 47.86% of the company’s stock.

Profound Medical Stock Up 8.3 %

Profound Medical stock opened at $5.23 on Friday. Profound Medical Corp. has a 52 week low of $3.90 and a 52 week high of $11.42. The firm has a market cap of $157.18 million, a price-to-earnings ratio of -3.90 and a beta of 0.68. The business’s 50-day moving average price is $5.79 and its 200 day moving average price is $6.83. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11.

Profound Medical (NASDAQ:PROF) last posted its earnings results on Thursday, March 6th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.11. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. The firm had revenue of $4.18 million during the quarter, compared to analyst estimates of $5.92 million. As a group, sell-side analysts anticipate that Profound Medical Corp. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Lake Street Capital reduced their target price on shares of Profound Medical from $17.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd.

Profound Medical Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.